WCN25-4378 OUTCOME OF USE OF ENTERIC RELEASED BUDESONIDE IN IgA NEPHROPATHY PATIENTS WITH NEPHROTIC AND SUBNEPHROTIC PROTEINURIA PRESENTATIONS: PROSPECTIVE COMPARATIVE STUDY IN TERTIARY CARE CENTRE
Saved in:
| Main Authors: | RAJA SINGHAL, ARPITA RAY CHAUDHARY |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924024744 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
WCN25-932 STEROID (SYSTEMIC OR ENTERIC RELEASED BUDESONIDE) REFRACTORY NEPHROTIC RANGE PROTEINURIA IN IgA NEPHROPATHY; CAN TACROLIMUS BE AN ALTERNATIVE?- A CASE SERIES
by: RAJA SINGHAL, et al.
Published: (2025-02-01) -
Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide
by: Christodoulos Keskinis, et al.
Published: (2025-04-01) -
Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics
by: Mengshu Lin, et al.
Published: (2025-08-01) -
WCN25-3679 Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy
by: SANSHRITI CHAUHAN, et al.
Published: (2025-02-01) -
A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment
by: Yan Ouyang, et al.
Published: (2025-03-01)